Ixabepilone and Pemetrexed/Solid Tumors

Inclusion Criteria

• •SWOG performance status of 0-2.
• •Projected life expectancy of at least 3 months.
• •Female and or male age 18 years and over.
• •Provision of informed consent prior to any study-related procedures.
• •Female patients must not be pregnant due to the potential mutagenicity. and teratogenicity of this treatment. A pregnancy test must be administered 7 days prior to administration of therapy to women of childbearing potential.
• •Negative pregnancy test for women of childbearing potential.
• •Patients must agree to use some form of contraception while on this study at initiation and for the duration of participation in the study. Sexually active males must also use a reliable and appropriate method of contraception. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
• •Patients must have recovered from acute toxicities from previous surgery, chemotherapy or radiation therapy.
• •Adequate organ function defined as:
• •* ANC \> 1500/mm3
• •* Platelet count \> 100,000 cells/mm3
• •* Hemoglobin \> 9.0g/dL
• •* Serum creatinine \< 1.5 mg/dl or creatinine clearance \> 45 mL/minute
• •* (calculated by Cockcroft-Gault formula.)
• •* Hepatic function: Patients must have adequate liver functions: AST or ALT \< 2.5 X upper limit of normal (ULN), alkaline phosphatase \< 2.5 X upper limit of normal. In patients with bone metastasis and no evidence of liver metastasis and bilirubin \< upper limit of normal an alkaline phosphatase \< 5 ULN will be allowed
• •* Serum Bilirubin \< 1.5 mg/dL
• •Peripheral neuropathy grade 0-1.
• •No other concomitant therapy directed at the cancer is allowed.
• •The ability to interrupt NSAIDS 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed.
• •The ability to take folic acid, Vitamin B12, and dexamethasone according to protocol.